Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: K14R 99% (n=2,129) • E35D 100% (n=3,185) • M36I 100% (n=3,186) • R41K 99% (n=3,172) • H69K 99% (n=2,513) • L89M 100% (n=2,858)

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: None
RT Other Mutations: E6D 100% (n=2,326) • V8I 100% (n=2,811) • V35T 99% (n=2,380) • K49R 94% (n=1,974) • V60I 99% (n=1,101) • K122E 99% (n=859) • I135T 100% (n=2,502) • K173L 100% (n=1,939) • Q174K 100% (n=1,935) • D177E 99% (n=1,939) • V179I 99% (n=1,771) • I202V 100% (n=903) • Q207E 100% (n=975) • R211K 99% (n=972) • P243S 96% (n=111) • V245K 100% (n=83) • K249Q 100% (n=97) • A354S 96% (n=224)

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

RT comments

Other

- **V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: None
IN Other Mutations: K14R 100% (n=728) • V31I 100% (n=893) • M50MI M: 61%, I: 39% (n=875) • I72V 98% (n=855) • T112IV V: 68%, I: 35% (n=252) • I113V 95% (n=252) • T124A 99% (n=258) • T125A 100% (n=258) • V126F 100% (n=258) • I135V 93% (n=836) • I161IL L: 72%, I: 24% (n=872) • V165VI V: 80%, I: 20% (n=825) • D167E 100% (n=818) • V201I 100% (n=797) • K211R 100% (n=733) • T218S 100% (n=825) • N222K 99% (n=844) • L234I 99% (n=832) • S283G 100% (n=813) • R284G 100% (n=813)

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

IN comments

Other

- **M50I** is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-naïve persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It may contribute to reduced DTG and CAB susceptibility in combination with R263K.

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.